NetworkNewsWire Editorial Coverage: A tsunami has started: Cannabidiol (CBD), a non-psychoactive compound found in the cannabis sativa plant, has shown tremendous promise for broad-ranging medical benefits, and consumers are taking notice. CBD products are derived from either industrial hemp or marijuana plants, and sales have soared as companies scramble to exploit the enormous opportunity. Total CBD sales exceeded $200 million in 2016, and conservative projections peg overall sales in excess of $2.1 billion by 2020, a 700% increase from 2016. The hemp-derived CBD market is projected to grow at an astounding compounded annual growth rate approaching 55% over the next five years, positioning it as the fastest growing sub-segment within the multi-billion-dollar legal cannabis and hemp market. Some of the most promising players in the space include PotNetwork Holding Inc. (POTN) (POTN Profile), given a four-fold price target by a an equity research firm, Terra Tech Corp (TRTC), INSYS Therapeutics Inc. (INSY), Cannabis Science Inc. (CBIS) and 22nd Century Group Inc. (XXII).
Thousands of scientific studies tout the benefits of medical CBD. Research continues to be encouraging for CBD’s anti-seizure properties, singularly effective in treating certain epilepsies. Its effect on epilepsy and lack of significant side effects makes CBDs an attractive treatment option for multiple neurological disorders such as neurodegeneration, neuronal injury, and psychiatric diseases. CBD significantly reduces inflammation, and is already used to treat chronic pain, multiple sclerosis, and fibromyalgia. CBD has also demonstrated promising therapeutic results treating multiple anxiety disorders, mood symptoms, rheumatoid arthritis, nausea and insomnia. But the list of benefits is only growing. It appears to ease inflammation in the pancreas in Type 1 diabetes; there’s evidence that it has potential to prevent Alzheimer’s disease symptoms; and CBD appears to suppress the growth of cancer cells and promote the death of these cells (http://nnw.fm/Gag71). In multiple studies, CBD has been well-tolerated in adults across a wide range of dosages. With so many direct applications, the prospects of combination pharmaceutical therapies and the promise of a myriad of new remedies, it is little wonder the CBD market is exploding, and companies are vying to capitalize on the immense opportunity.
Through its subsidiaries, PotNetwork Holding (POTN) researches, develops and sells premium hemp extracts throughout the U.S. and internationally. The company’s products are made with federally legal hemp-derived CBD, and are available in a variety of flavors and sizes tailored to exceed consumer needs and expectations. As the primary operating entity of PotNetwork, Diamond CBD, Inc. produces and markets 15 different CBD brands that have gained international acceptance for both quality and consistency. With its staff of scientists and chemists, Diamond CBD develops and produces only the highest quality CBD oil across multiple product lines for specific medicinal uses. Scientific research and depth of knowledge of natural hemp molecules and their properties determine the course of new product development. The company insists on 100% natural lab-tested CBD ingredients, with the process meticulously monitored from the source farm through every stage of production and final delivery to retail outlets.
To deliver and expand products of exceptional quality and efficacy, PotNetwork is building a team of medical professionals with knowledge and expertise in the intricacies of CBD and how to best achieve optimal therapeutic results. Keeping with strategy, PotNetwork recently appointed Dr. Richard Goulding, MD as its chief executive officer (http://nnw.fm/6HEfH). A veteran of medical science with extensive knowledge of CBD’s prophylactic benefits, Dr. Goulding will be instrumental in directing the company’s mission to develop scientifically targeted formulas designed to deliver consistent results for a wide spectrum of maladies. His insight on the latest research utilizing cannabis for multiple medical applications is expected to strongly enhance the company’s ability to excel in the marketplace. As Dr. Goulding stated in a press release announcing his appointment, “From what I’ve been able to discover, it seems we have only scratched the surface in this marketplace. It truly is an optimum time to be involved in an industry whose time has come.”
Not alone in his assessment, equity research firm SeeThruEquity identifies a “burgeoning legal cannabis and hemp industry,” and said it expects PotNetwork to increase YOY revenues 712% in fiscal year 2017, driven by new product launches, aggressive marketing initiatives, and entry into new markets (http://nnw.fm/xZ4jH). The report sets a price target of $0.25 per share for POTN, four times the current level. PotNetwork has 484 million shares outstanding and a market capitalization of $29 million.
As a cannabis-focused agriculture company, Terra Tech Corp. (TRTC) produces, extracts and distributes medical cannabis, and is engaged in plant science research and development, food production, and closed environment agriculture. The company operates through multiple subsidiary businesses, including: Blüm, its retail and medical cannabis facilities; IVXX Inc., which produces cannabis extracted products for medical cannabis dispensaries in California and Nevada; Edible Garden, which cultivates and sells local and sustainably grown hydroponic produce; and MediFarm LLC, which is focused on medical and adult-use cannabis cultivation and permitting businesses in Nevada. The company has nearly 665 million shares outstanding and carries a hefty $135+ million market capitalization.
INSYS Therapeutics Inc. (INSY) develops and commercializes innovative drugs and drug delivery systems. INSYS currently markets two products: Subsys®, which is sublingual Fentanyl spray for breakthrough cancer pain; and a generic version of Dronabinol, a synthetic chemical form of tetrahydrocannabinol (THC). In 2011, the company launched its Dronabinol SG Capsule, a generic equivalent to Marinol (synthetic THC), an approved second-line treatment for chemotherapy-induced nausea and vomiting and anorexia associated with weight loss in AIDS patients. In 2012, the company launched its proprietary sublingual fentanyl spray for breakthrough cancer pain. Since late 2014, Subsys® has been the most prescribed transmucosal immediate-release fentanyl product with 48% market share on a prescription basis. This enormous market share is in part explanatory of the company’s eye-popping 203 PE ratio and a market cap of $664 million. There are almost 73 million shares outstanding and big money is well positioned with 28% institutional ownership.
Engaged in medical marijuana research and development, Cannabis Science Inc. (CBIS) works on phytocannabinoids to target critical illnesses and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. The company is involved in the creation of cannabis-based medicines, with and without psychoactive properties, to treat disease and the symptoms of disease. Cannabis Science’s products are medical cannabinoid formulations developed from one or more of the cannabinoid compounds found in the cannabis plant and the company focuses on development of governmentally approved pharmaceuticals. The company has 2.5 billion shares outstanding and market cap of $87 million.
Through genetic engineering and plant breeding, 22nd Century Group Inc. (XXII) can increase or decrease the level of nicotine and nicotinic alkaloids in tobacco plants and the levels of cannabinoids in cannabis plants. The company’s primary mission in tobacco is to reduce the harm caused by smoking and its primary mission in cannabis is to develop proprietary hemp/cannabis strains for new medicines and agricultural crops. The company is engaged in research and development of specialized plant varieties of hemp/cannabis, such as plants with low to no amounts of THC; plants with high levels of CBD and other non-THC cannabinoids; research and development of less harmful tobacco products and tobacco plant varieties; and a smoking cessation aid consisting of very low nicotine cigarettes. Not a pure CBD play, the company has 102 million shares outstanding and a market cap of $293 million.
According to research from Brightfield Group and HelloMD, 80 percent of all people who use CBD found the products to be “very or extremely effective,” and nearly half of all CBD users actually stop taking traditional medications like Tylenol or prescription drugs like Vicodin, as reported by Forbes (http://nnw.fm/30jLR). With such overwhelming endorsement by retail consumers of medicinal cannabidiol, there is little doubt that CBD is becoming a mainstream therapeutic that will continue to grow in market size and acceptance.
For more information on PotNetwork Holding Inc., visit PotNetwork Holding (POTN)
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.